Biotechnology investing slowed a bit in 2003, along with the rest of venture dealmaking, but a string of big bets on cancer therapeutics in January could augur a healthy recovery for the sector this year.
Biotechnology investing slowed a bit in 2003, along with the rest of venture dealmaking, but a string of big bets on cancer therapeutics in January could augur a healthy recovery for the sector this year.
